Pediatric Supplements Market 2023 A Status of Top Regions and Companies with Growth Prospects - Benzinga
| ABL Stock | 109.66 1.56 1.44% |
Slightly above 53% of Abbott Laboratories' private investors are presently thinking to get in. The analysis of current outlook of investing in Abbott Laboratories suggests that some traders are interested regarding Abbott Laboratories' prospects. Abbott Laboratories' investing sentiment can be driven by a variety of factors including economic data, Abbott Laboratories' earnings reports, geopolitical events, and overall market trends.
Abbott |
Pediatric Supplements Market 2023 A Status of Top Regions and Companies with Growth Prospects Benzinga
Read at news.google.com
 |
Abbott Laboratories Fundamental Analysis
We analyze Abbott Laboratories' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abbott Laboratories using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abbott Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Abbott Laboratories is number one stock in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Abbott Laboratories Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Abbott Laboratories stock to make a market-neutral strategy. Peer analysis of Abbott Laboratories could also be used in its relative valuation, which is a method of valuing Abbott Laboratories by comparing valuation metrics with similar companies.
Peers
Abbott Laboratories Related Equities
| ABL | Abbott Laboratories | 1.44 | ||||
| SYK | Stryker | 1.25 | ||||
| EWL | Edwards Lifesciences | 0.37 | ||||
| 2M6 | Medtronic PLC | 0.22 | ||||
| SHL | Siemens Healthineers | 0.72 | ||||
| BSX | Boston Scientific | 1.16 | ||||
| AFW | Align Technology | 1.61 |
Additional Tools for Abbott Stock Analysis
When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.